Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REP 2139

Next Previous
Drug Profile

REP 2139

Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'

Latest Information Update: 07 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REPLICor
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Hepatitis B; Hepatitis D

Most Recent Events

  • 17 Jan 2025 Replicor terminates Replicor compassionate access Program (RCAP) in Hepatitis D in Austria, France, Israel, Italy and Turkey (SC) (NCT05683548)
  • 15 Nov 2024 Pharmacodynamics data from a preclinical trial in Hepatitis D presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
  • 05 Jun 2024 Efficacy data from the REPLICor Compassionate Access Program in Hepatitis B and Hepatitis D presented at European Association for the Study of the Liver Congress 2024 (EASL-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top